Efficacy of Celecoxib Vs Placebo to Prevent Pain in a Paced Walk
NCT00194090
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
(216) 591-1443
Knee osteoarthritis by ACR clinical criteria Pain of at least 40 mm by VAS at baseline
-
Non-pregant, non-lactating Able to stop active arthritis medication for washout
Cardiovascular risk factors Abnormal EKG -
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Boston, Massachusetts
- Cleveland, Ohio
- Funabashi, Chiba
- Sakura, Chiba
- Chikushi-gun, Fukuoka
- Iizuka, Fukuoka
- Kurume, Fukuoka
- Yame, Fukuoka
- Chitose, Hokkaido
- Sapporo, Hokkaido
- Kamakura, Kanagawa
- Yokohama, Kanagawa
- Isahaya, Nagasaki
- Hirakata, Osaka
- Kanzaki-gun, Saga
- Karatsu, Saga
- Ogi-gun, Saga
- Itabashi-ku, Tokyo
- Setagaya-ku, Tokyo
- Shinjuku-Ku, Tokyo
- Taito-ku, Tokyo
- Yoyogi Shibuya-ku, Tokyo
- Saga,
- Tokyo,
- Bad Muender,
- Beckum,
- Berlin,
- Berlin,
- Berlin,
- Berlin,
- Ostseebad Damp,
- Schwerin,
- Stade,
- Tostedt,
- Weener,
- Barcelona,
- Barcelona,
- Cadiz,
- Guadalajara,
- Madrid,
- Madrid,
- Madrid,
- Oviedo,
- Sevilla,
- Valencia,
- Chelmsly Wood, Birmingham
- Truro, Cornwall
- Chorley, Lancs
- Liverpool, Lancs
- Cannock, Mid Staffordshire
- Addlestone, Surrey
- Huddersfield,
- London,
- London,
- Manchester,
- Newcastle Upon Tyne,
- Wigan,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Efficacy of Celecoxib Vs Placebo to Prevent Pain in a Paced Walk | |||
Official Title ICMJE | A Double-Blind, Placebo-Controlled, Crossover Pilot Study of the Efficacy of Celecoxib 200 Mg Qd in Relieving Pain and Walking Dysfunction in Osteoarthritis of the Knee | |||
Brief Summary | A paced 20-minute walk is a reproducible model for acute pain in knee osteoarthritis | |||
Detailed Description | This is a randomizd, placbo-controlled, crossover trial comparing a single dose of celecoxib to placebo measuring the time to onset of acute pain in a paced 20-minute walk. 40 subjects will be enrolled | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 4 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Crossover Assignment Masking: Double Primary Purpose: Treatment | |||
Condition ICMJE | Knee Osteoarthritis | |||
Intervention ICMJE | Drug: celecoxib | |||
Study Arms ICMJE | Not Provided | |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Unknown status | |||
Enrollment ICMJE | 40 | |||
Original Enrollment ICMJE | Same as current | |||
Study Completion Date ICMJE | September 2005 | |||
Primary Completion Date | Not Provided | |||
Eligibility Criteria ICMJE | Inclusion Criteria: Knee osteoarthritis by ACR clinical criteria Pain of at least 40 mm by VAS at baseline - Exclusion Criteria: Non-pregant, non-lactating Able to stop active arthritis medication for washout Cardiovascular risk factors Abnormal EKG - | |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 45 Years to 85 Years (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00194090 | |||
Other Study ID Numbers ICMJE | 06-04-41 | |||
Has Data Monitoring Committee | Not Provided | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Not Provided | |||
Study Sponsor ICMJE | University Hospitals Cleveland Medical Center | |||
Collaborators ICMJE | Pfizer | |||
Investigators ICMJE |
| |||
PRS Account | University Hospitals Cleveland Medical Center | |||
Verification Date | July 2004 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |